Nicholas J White et al | 14 Dec 2012 | Malaria Journal
In areas of low malaria transmission, it is currently recommended that a single dose of primaquine (0.75 mg base/kg; 45 mg adult dose) be added to artemisinin combination treatment (ACT) in acute falciparum malaria to block malaria transmission.
Roger Bate & Kimberly Hess | 05 Dec 2012 | MalariaWorld Journal
Most donor agencies only procure drugs approved by a Stringent Regulatory Authority or the World Health Organization (WHO) Prequalification Programme in an effort to ensure high quality. However...
Matthew Hilburn | 29 Nov 2012 | Voice of America
A new diagnostic test could revolutionize the treatment of malaria, one of the world's most persistent and deadly diseases, making it possible to diagnose the illness from a single drop of blood or saliva.
Phyllis Awor et al | 19 Nov 2012 | American Journal of Tropical Medicine and Hygiene
We conducted a survey involving 1,604 households to determine community care-seeking patterns and 163 exit interviews to determine appropriateness of treatment of common childhood illnesses at private sector drug shops in two rural districts of Uganda.
Carlos J Chaccour et al | 22 Sep 2012 | The Lancet
In October, 2011, a previously well 28-year-old woman from Spain was admitted to our hospital with a 5 day history of fever, rigors, headache, back pain, and myalgia.
Prashant Yadav et al | 28 Aug 2012 | Malaria Journal
The AMFm led to large increases in availability of low priced ACT in Tanzania, with no significant variation in availability based on remoteness. Availability did remain lower and prices remained higher in Rukwa, which
is a more remote region overall.
Joshua Yukich et al | 13 Aug 2012 | American Journal of Tropical Medicine and Hygiene
Rapid diagnostic tests may contribute to rationalization of treatment of febrile illness and reduce antimalarial drug consumption in Africa; however, their impact may be greater in lower transmission areas. National scale data will be necessary to confirm these findings.
James Kisia et al | 30 Jul 2012 | Malaria Journal
The potential for utilization of CHWs in improving access to malaria treatment at the community level is promising.
Roger Bate et al | 18 Jul 2012 | Research and Reports in Tropical Medicine
The AMFm is at best imperfectly displacing undesirable monotherapies, some portion of which are replaced by ACTs lacking sufficient API, which are often sold at prices exceeding government authorization.
Roger Bate et al | 16 Jul 2012 | Research and Reports in Tropical Medicine
The results strongly indicate that approval by either an SRA or the WHO is correlated with higher medicine quality at a statistically significant level. The comparatively high failure rates among WHO-approved products suggest there may be some weakness in post-marketing surveillance of these products, especially of Chinese-made WHO-approved products.